A detailed history of Vanguard Group Inc transactions in Siga Technologies Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,283,612 shares of SIGA stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,283,612
Previous 2,242,097 1.85%
Holding current value
$16.8 Million
Previous $12.6 Million 55.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.51 - $8.92 $187,232 - $370,313
41,515 Added 1.85%
2,283,612 $19.5 Million
Q4 2023

Feb 14, 2024

BUY
$4.82 - $6.25 $189,040 - $245,125
39,220 Added 1.78%
2,242,097 $12.6 Million
Q3 2023

Nov 14, 2023

BUY
$4.32 - $5.77 $35,445 - $47,342
8,205 Added 0.37%
2,202,877 $11.6 Million
Q2 2023

Aug 14, 2023

SELL
$5.0 - $6.31 $263,635 - $332,707
-52,727 Reduced 2.35%
2,194,672 $11.1 Million
Q1 2023

May 15, 2023

SELL
$5.23 - $8.42 $120,399 - $193,836
-23,021 Reduced 1.01%
2,247,399 $12.9 Million
Q4 2022

Feb 10, 2023

BUY
$7.29 - $10.14 $303,344 - $421,935
41,611 Added 1.87%
2,270,420 $16.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.02 - $26.15 $695,618 - $1.82 Million
69,423 Added 3.21%
2,228,809 $23 Million
Q2 2022

Aug 12, 2022

SELL
$6.5 - $13.68 $488,351 - $1.03 Million
-75,131 Reduced 3.36%
2,159,386 $25 Million
Q1 2022

May 13, 2022

SELL
$5.96 - $7.61 $959 - $1,225
-161 Reduced 0.01%
2,234,517 $15.8 Million
Q4 2021

Feb 14, 2022

SELL
$6.96 - $9.26 $21,548 - $28,668
-3,096 Reduced 0.14%
2,234,678 $16.8 Million
Q3 2021

Nov 12, 2021

SELL
$5.71 - $7.39 $770,307 - $996,947
-134,905 Reduced 5.69%
2,237,774 $16.5 Million
Q2 2021

Aug 13, 2021

BUY
$6.1 - $7.58 $14.5 Million - $18 Million
2,372,679 New
2,372,679 $14.9 Million

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $538M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.